The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases : An analysis of the national pharmacovigilance database in South Korea
© 2021 The Authors. Journal of Digestive Diseases published by Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd..
OBJECTIVE: The objective of this case/non-case study was to detect rebamipide-related pulmonary adverse events (AE) compared with other drugs for acid-related disorders based on population-level data.
METHODS: From 2009 to 2018, AE reports on drugs for acid-related disorders, which are anatomical therapeutic chemical code A02B drugs, in the Korea Adverse Events Reporting System (KAERS) database were examined. The reporting odds ratio (ROR) was calculated, and the odds of reporting pulmonary AE for rebamipide and all other A02B drugs were compared. Furthermore, a stratified analysis according to patients' age and sex was conducted.
RESULTS: Altogether 13 (0.05%) and 157 (0.11%) cases of pulmonary AE were reported for rebamipide and all other A02B drugs, respectively. The risk of reporting pulmonary AE was significantly lower for rebamipide than for all other A02B drugs (ROR 0.49, 95% confidence interval [CI] 0.28-0.87). The number of reports of pulmonary AE for rebamipide was significantly higher among patients aged ≥65 years than those aged <65 years (ROR 19.36, 95% CI 2.50-149.97).
CONCLUSIONS: Rebamipide was less often reported for pulmonary AE. However, healthcare professionals need to be aware of the risk of pulmonary AE in elderly patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of digestive diseases - 23(2022), 2 vom: 28. Feb., Seite 118-123 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Bo Ram [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alanine |
|---|
| Anmerkungen: |
Date Completed 07.03.2022 Date Revised 29.07.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1751-2980.13075 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335008275 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335008275 | ||
| 003 | DE-627 | ||
| 005 | 20231225224912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1751-2980.13075 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM335008275 | ||
| 035 | |a (NLM)34965009 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Bo Ram |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases |b An analysis of the national pharmacovigilance database in South Korea |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2022 | ||
| 500 | |a Date Revised 29.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Journal of Digestive Diseases published by Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a OBJECTIVE: The objective of this case/non-case study was to detect rebamipide-related pulmonary adverse events (AE) compared with other drugs for acid-related disorders based on population-level data | ||
| 520 | |a METHODS: From 2009 to 2018, AE reports on drugs for acid-related disorders, which are anatomical therapeutic chemical code A02B drugs, in the Korea Adverse Events Reporting System (KAERS) database were examined. The reporting odds ratio (ROR) was calculated, and the odds of reporting pulmonary AE for rebamipide and all other A02B drugs were compared. Furthermore, a stratified analysis according to patients' age and sex was conducted | ||
| 520 | |a RESULTS: Altogether 13 (0.05%) and 157 (0.11%) cases of pulmonary AE were reported for rebamipide and all other A02B drugs, respectively. The risk of reporting pulmonary AE was significantly lower for rebamipide than for all other A02B drugs (ROR 0.49, 95% confidence interval [CI] 0.28-0.87). The number of reports of pulmonary AE for rebamipide was significantly higher among patients aged ≥65 years than those aged <65 years (ROR 19.36, 95% CI 2.50-149.97) | ||
| 520 | |a CONCLUSIONS: Rebamipide was less often reported for pulmonary AE. However, healthcare professionals need to be aware of the risk of pulmonary AE in elderly patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a KIDS KAERS database | |
| 650 | 4 | |a drug-related side effects and adverse reactions | |
| 650 | 4 | |a interstitial lung diseases | |
| 650 | 4 | |a pharmacovigilance | |
| 650 | 4 | |a rebamipide | |
| 650 | 7 | |a Quinolones |2 NLM | |
| 650 | 7 | |a rebamipide |2 NLM | |
| 650 | 7 | |a LR583V32ZR |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Lee, Jae-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Myeong Gyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of digestive diseases |d 2007 |g 23(2022), 2 vom: 28. Feb., Seite 118-123 |w (DE-627)NLM168045079 |x 1751-2980 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:2 |g day:28 |g month:02 |g pages:118-123 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1751-2980.13075 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 2 |b 28 |c 02 |h 118-123 | ||